The initiating oncogenic event in almost half of human lung adenocarcinomas is still unknown, a fact that complicates the development of selective targeted therapies. Yet these tumours harbour a number of alterations without obvious oncogenic function including BRAF-inactivating mutations. Inactivating BRAF mutants in lung predominate over the activating V600E mutant that is frequently observed in other tumour types
The initiating oncogenic event in almost half of human lung adenocarcinomas is still unknown, a fact that complicates the development of selective targeted therapies. Yet these tumours harbour a number of alterations without obvious oncogenic function including BRAF-inactivating mutations. Inactivating BRAF mutants in lung predominate over the activating V600E mutant that is frequently observed in other tumour types 1 . Here we demonstrate that the expression of an endogenous Braf(D631A) kinase-inactive isoform in mice (corresponding to the human BRAF(D594A) mutation) triggers lung adenocarcinoma in vivo, indicating that BRAF-inactivating mutations are initiating events in lung oncogenesis. Moreover, inactivating BRAF mutations have also been identified in a subset of KRAS-driven human lung tumours. Co-expression of Kras(G12V) and Braf(D631A) in mouse lung cells markedly enhances tumour initiation, a phenomenon mediated by Craf kinase activity 2, 3 , and effectively accelerates tumour progression when activated in advanced lung adenocarcinomas. We also report a key role for the wild-type Braf kinase in sustaining Kras(G12V)/ Braf(D631A)-driven tumours. Ablation of the wild-type Braf allele prevents the development of lung adenocarcinoma by inducing a further increase in MAPK signalling that results in oncogenic toxicity; this effect can be abolished by pharmacological inhibition of Mek to restore tumour growth. However, the loss of wild-type Braf also induces transdifferentiation of club cells, which leads to the rapid development of lethal intrabronchiolar lesions. These observations indicate that the signal intensity of the MAPK pathway is a critical determinant not only in tumour development, but also in dictating the nature of the cancer-initiating cell and ultimately the resulting tumour phenotype.
The RAS-MAPK signalling cascade serves as a central node in transducing signals from membrane receptors to the nucleus. This pathway is aberrantly activated in a substantial fraction of human cancers 4 . Moreover, germline mutations resulting in limited activation of this signalling cascade cause developmental disorders known as RASopathies 5 .
There is also abundant evidence that elevated RAS-MAPK signalling results in cellular toxicity that may serve as a natural barrier to cancer progression early in tumorigenesis 6 . Finally, genetic abrogation of this pathway in adult mice results in their rapid death 7 . These findings suggest that defined thresholds of RAS-MAPK activity are required for homeostasis as well as for malignant transformation, but compelling genetic evidence is missing.
In order to augment MAPK signalling in controlled increments we have taken advantage of the expression of an endogenous Braf(D631A) kinase-dead isoform (corresponding to the human BRAF(D594A) mutant) that is known to induce Erk phosphorylation in a Crafdependent manner 2, 8 . This effect, known as the MAPK paradox, is due to enhanced heterodimerization and activation of the catalytically competent Craf protomer in Braf(D631A)-Craf complexes 2, 3 . In agreement with these observations, lack of wild-type Braf expression in Kras G12V cell lines expressing Braf(D631A) increased the intensity and duration of MAPK signalling (Extended Data Fig. 1 Lung cells expressing these conditional alleles were identified by co-expression of the Kras(G12V) oncoprotein with β-geo, a chimaeric bacterial protein with β-galactosidase activity 9 (Extended Data Fig. 2 ). As illustrated in Fig. 1a , small X-gal + hyperplasias could be readily detected in the lungs of K mice 1 month after Ad-Cre infection. By constrast, Ad-Cre-infected KB mice displayed abundant hyperplastic areas together with adenomas, a lesion that is extremely infrequent in K mice at this early stage 10 . Remarkably, X-gal + alveolar hyperplasias and adenomas were nearly absent in Ad-Cre-infected KBL animals. These mice, however, displayed hypertrophic bronchi as their most prominent feature (Fig. 1a) . The lack of Kras G12V -driven alveolar lesions in KBL mice is unlikely to be a consequence of the absence of an active Braf, since this kinase is dispensable for the development of Kras
G12V
-driven lung adenocarcinoma 7, 11 . Thus, we explored the possibility that the absence of alveolar lesions was due to some sort of cellular toxicity such as that caused by the induction of senescence or DNA damage, two phenomena known to act as barriers to tumour development 6, 12, 13 . Indeed, examination of lung lysates and sections from KBL mice detected p19
Arf and p53 tumour suppressors, active caspase-3 and γ-H2AX, a marker for DNA damage, as early as 1 week following Ad-Cre infection (Fig. 1b, c) . We did not observe differences in senescence-associated β-gal staining (data not shown). The concomitant increase in the phosphorylation of Erk1/2 and p90Rsk suggested that elevated MAPK signalling triggered a stress response that impaired tumour cell proliferation. Yet it has been recently described that mutant Kras-driven lung adenocarcinomas display a tonic activation of the DNA damage response to prevent the induction of genotoxic stress 14 . We hypothesize that the exclusive formation of Braf(D631A)-Craf complexes in KBL mice exceeded such a toxic signalling threshold and induced a stress response incompatible with tumour development. Thus, our results indicate that Ras-oncogenic toxicity is quantitatively dictated by MAPK function. In support of this hypothesis, whereas Mek inhibition prevented tumour growth in Ad-Cre-infected KB mice, it rescued the toxic phenotype in KBL animals in a dose-dependent manner and restored tumour progression at intermediate drug concentrations, most likely by curtailing MAPK activity to levels compatible with cell proliferation (Fig. 1d) . This is in agreement with the observation that RASinduced senescence in primary cells is bypassed by inhibition of MEK and ERK kinases 15 . These observations suggest that Kras
-driven lung tumour cells can only proliferate within a limited range of MAPK activity. Whereas excess MAPK activity induced DNA damagemediated cellular toxicity, insufficient MAPK signalling cannot sustain tumour growth.
Next, cohorts of Ad-Cre infected K, KB and KBL mice were followed over time. In agreement with the earlier onset and the more rapid progression of the alveolar lesions, the KB animals displayed significantly shortened survival (Fig. 2a) . Histopathological analysis of their lungs at 6 months post Ad-Cre infection revealed a 7.5-fold increase in tumour burden compared to K controls (Fig. 2b) . Moreover, KB mice displayed advanced adenocarcinomas, a tumour stage that is extremely infrequent at this time in tumours driven by Kras G12V alone (Fig. 2c ). Tumours present in KB mice displayed SPC + CC10 − immunostaining, which suggests an alveolar type II (AT2) origin as previously described for adenocarcinomas driven by oncogenic Kras alone 10, 16 (Fig. 2d) . Altogether, these observations suggest that MAPK hyperactivation by coexisting Kras(G12V) and Braf(D631A) mutations resulted in increased transformation of AT2 cells and accelerated tumour progression. The MAPK paradoxical activation model postulates that the observed tumour phenotype is mediated by Craf kinase activity 2, 8, 17 . To genetically validate this hypothesis in the lung tumours studied here, we added conditional knock-in Craf (also known as Raf1) kinase-dead alleles (Craf
LSLD468A
) to KB mice. The resulting strain, Kras
;Braf
;Craf LSLD468A/LSLD468A (designated as KBC KD ) was used to determine whether genetic inhibition of the Craf kinase reverted the increased tumorigenic phenotype displayed by KB mice. Expression of the Craf(D468A) kinase-dead isoform led (KBL, open triangles, n = 17) mice after Ad-Cre intratracheal infection. P < 0.0001, obtained using the log-rank test (Mantel-Cox). b, Quantification of average tumour (adenoma and adenocarcinoma) burden (per cent of total lung area) in lung sections from Kras +/LSLG12Vgeo (K, n = 5), Kras +/LSLG12Vgeo ;Braf +/LSLD631A (KB, n = 7) and Kras +/LSLG12Vgeo ;Braf lox/LSLD631A (KBL, n = 7) mice 6 months after Ad-Cre intratracheal infection. **P < 0.01, *P < 0.05. c, Representative haematoxylin and eosin staining of paraffin-embedded lung sections obtained from Kras
(KB, n = 7) and Kras +/LSLG12Vgeo ;Braf lox/LSLD631A (KBL, n = 7) mice 6 months after Ad-Cre infection. Scale bar, 5 mm. d, Representative immunostaining of paraffin-embedded sections showing tumours from Ad-Cre-infected Kras +/LSLG12Vgeo ;Braf +/LSLD631A (KB, n = 7) mice killed at humane end point using antibodies against SPC and CC10. Scale bar, 1 mm. e, Quantification of average tumour (adenoma and adenocarcinoma) burden (per cent of total lung area) in lung sections from Kras +/LSLG12Vgeo ;Braf
(KB, n = 7) and Kras
;Craf LSLD468A/LSLD468A (KBC KD , n = 5) mice 6 months after Ad-Cre intratracheal infection. **P < 0.01. f, Representative haematoxylin and eosin staining of paraffin-embedded lung sections (n = 5 per genotype) from Kras +/LSLG12Vgeo ;Braf , empty squares, n = 7) mice after Ad-Cre intratracheal infection. P < 0.0001, obtained using the log-rank test (Mantel-Cox).
to a substantial decrease in the levels of phosphorylated (p-)Erk1/2 and overall tumour burden (Fig. 2e, f and Extended Data Fig. 3) , significantly extending the survival of Ad-Cre-infected KBC KD mice compared to KB animals. Similarly, Craf ablation (KBC L mice) also resulted in prolonged survival (Fig. 2g) . Altogether, these results demonstrate that the increased tumour burden and faster adenocarcinoma progression in KB animals is due to Craf-mediated hyperactivation of MAPK signalling.
As indicated above, the tumour burden of the KBL cohort was significantly decreased compared to KB mice, suggesting that excessive MAPK activity in the absence of wild-type Braf expression may be detrimental for lung adenocarcinoma development. Yet, in spite of the reduced tumour burden, KBL animals reached humane end point at the same time as KB mice (Fig. 2a, b) . Detailed examination of the lungs of KBL mice revealed the presence of intrabronchiolar carcinomas (112 of 250 bronchi, 45%), a rare lesion in K (0 of 162) or KB (20 of 145, 14%) cohorts (Fig. 3a) . Immunostaining with a collection of markers including Ttf1 and SPC, characteristic of lung adenocarcinoma and Sox2, p63 and CK5, diagnostic of squamous cell carcinoma, did not clarify the origin of these intrabronchiolar lesions since the resulting expression pattern was not in accordance with the expected profile of either of these tumour types 18 ( Fig. 3b) . Analysis of the initial tumour stages of these lesions revealed protruding papillary structures accompanied by loss of CC10 expression, a marker characteristic of the bronchiolar epithelium. Most of these lesions (95%) acquired expression of the AT2 marker SPC, thus suggesting a transdifferentiation process (Fig. 3c and Extended Data Fig. 4) .
To further clarify the origin of these intrabronchiolar lesions we performed in vivo tracing experiments by infecting K, KB and KBL mice with lineage-specific Ad-CC10-Cre or Ad-SPC-Cre viruses that restrict Cre-mediated recombination to club or AT2 cells respectively 19 . Analysis of lungs of K and KB mice after Ad-SPC-Cre infection revealed the presence of adenomas that, as expected, were larger and more abundant in KB animals. Likewise, KBL mice predominantly developed alveolar hyperplasias that failed to progress to advanced stages. Importantly, infection with Ad-CC10-Cre did not induce tumour growth in K or KB mice but caused abundant SPC + intrabronchiolar carcinomas in KBL animals (Fig. 3d, e) . These results indicate that the threshold of MAPK activity toxic for AT2 cells resulted in the efficient transformation of cells present in bronchial epithelium that are usually refractory to Kras G12V -driven oncogenesis 10, 20, 21 . Altogether, these results suggest a quantitative impact of MAPK activity controlling various aspects of Kras oncogene-driven lung carcinogenesis. As such, oncogenic transformation may critically depend on cell-or tissue-specific programs that are hijacked to adjust MAPK activity and avoid senescence or other tumour-suppressive stress responses. This quantitative model is not exclusive to MAPK signalling as a similar threshold response level has been proposed for Wnt/β-catenin-driven 22 or PI3K/AKT-driven tumorigenesis 23 . Mutational analysis of different human cancers has recently uncovered that among the BRAF hot spots in lung adenocarcinoma, those resulting in inactivating mutations predominate over the V600E activating substitution 1 . However, the contribution of BRAF-inactive mutants to lung cancer progression is unclear. Interestingly, a percentage of BRAF-inactivating mutations (11%) coexist with upstream RAS alterations (Table 1) . Thus, we decided to investigate whether expression of the Braf(D631A) kinase-inactive mutant in pre-existing Kras G12V -driven tumours may enhance tumour progression. To this end, we added the Braf LSLD631A allele to a lung tumour model driven by the Flp recombinase. The resulting strain, Kras +/FSFG12V ; Tg.hUb-cre-ERT2 +/T ;Braf +/LSLD631A (designated as K F B) allows the temporal separation of tumour initiation (Flp-mediated Kras(G12V) expression) from genetic events induced during tumour progression (Cre-mediated Braf(D631A) expression). Induction of the Braf(D631A) kinase-inactive isoform in pre-existing Kras G12V -driven tumours Sample  BRAF  NF1  KRAS NRAS HRAS   TCGA-EE-A29N-06 D594N  Y80*  K117N  --TCGA-EE-A2GJ-06 G466E  --G12D  -TCGA-EE-A2GC-06 G466E  Q2239*  ---TCGA-EE-A19F-06 G466E  X69_splice, L274F  ---TCGA-EE-A1ZZ-06 N581S  Q684*, S1599F  -P34L  -TCGA-EE-A181- resulted in reduced survival owing to the accelerated progression of these lesions (Fig. 4a and Extended Data Fig. 5 ). Thus, these results provide an experimental explanation for the concurrence of oncogenic KRAS and BRAF-inactivating mutations in certain human lung tumours. These observations also reinforce the current clinical indication that class I RAF inhibitors (vemurafenib and derivatives targeting the activated form of the BRAF kinase) should not be used in patients with KRAS-mutant lung adenocarcinoma.
Yet, the majority of BRAF-inactivating mutations present in human lung cancer (89%) do not coexist with RAS mutations (Table 1) . To assess whether Braf inactive mutants could induce lung adenocarcinoma formation in the absence of Kras mutations, we infected Braf +/LSLD631A mice intratracheally with Ad-Cre. Analysis of their lungs 12 months after infection revealed the presence of tumours in 9 of 22 mice (41% incidence) compared to 14 of 18 (78%) in Kras
animals. All tumours studied displayed histology characteristic of lung adenocarcinoma with SPC +
CC10
− immunostaining (Fig. 4b and Extended Data Fig. 6a) . Notably, p-Erk1/2 levels in Braf
D631A
-driven lung adenocarcinomas were higher than those observed in Braf
V637E
(equivalent to human BRAF V600E ), Kras G12V or Kras G12V ;Trp53
-/-tumours (Fig. 4c) . As control, we confirmed that the Braf
LSLD631A
allele was efficiently recombined in tumour tissue. Moreover, we determined that there were no Ras mutations in these tumours (data not shown). These results suggest that Braf-inactivating mutations initiate lung adenocarcinoma (Extended Data Fig. 6b ). Our results are in good agreement with data from the Rosen laboratory indicating that increased levels of wild-type Ras-GTP complexes can cooperate with Braf hypoactive mutants to trigger tumour development in epithelial cells 24 . Similarly, increasing the pool of Ras-GTP by a dominant active Sos is sufficient to induce MAPK hyperactivation and the formation of epithelial tumours in response to Raf inhibition 25 . Likewise, MAPK activation in primary keratinocytes carrying the Braf LSLD631A allele depended both on Craf and RTK signalling. Of note, elimination of the Braf wild-type allele induced a further increase in p-Erk1/2 (Extended Data Fig. 6c) . In lung, the high levels of endogenous Ras-GTP present in adult AT2 cells 26 may explain the oncogenicity of the Braf(D631A) inactive mutant in the absence of Kras(G12V). By contrast, hypoactive BRAF mutants require the presence of RAS or NF1 mutations to trigger melanoma development, both in experimental GEM models 2 as well as in human tumours (Table 1) .
In summary, we provide the first genetic evidence demonstrating that a kinase-inactivating Braf mutation induces lung adenocarcinoma development. Importantly, in lung adenocarcinoma patients kinaseinactivating BRAF mutations are more prevalent than the activating V600E allele 1 . Furthermore, a recent retrospective study identified BRAF(D594G) (affecting the same residue as the mouse mutation used in this study) as the most frequent BRAF alteration in these patients 27 .
Our analysis of human lung adenocarcinomas with hypoactive BRAF revealed co-occurring alterations such as mutations in RTK signalling antagonists that might cooperate in sustaining MAPK activity (Extended Data Fig. 7 ). The accompanying manuscript by Yao et al. 24 suggests that RTK profiling of tumours driven by kinase-impaired BRAF mutants can identify the dominant receptor for the design of specific treatment for individual patients. Alternatively, our results suggest that these patients could benefit from therapies based on selective CRAF inhibitors. The mouse model described here will be useful to evaluate effective drug combinations.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. allele was generated by Gene Bridges GmBH. The D468A miscoding mutation (GAC (Asp) to GCC (Ala)) was engineered within the Craf locus present in the BAC RP23-37K24 by multi-site Red/ET ('triple recombination'). A loxP-cDNA-STOP-PGK-Neo-loxP cassette containing a partial Craf cDNA sequence encompassing exons 13 to 17 was inserted 150 bp upstream of the 5′ end of the mutated exon13 by Red/ET recombination. The resulting targeting vector was linearized with NotI and SalI restriction enzymes and electroporated into B6129SF1/J ES cells. Clones having undergone proper homologous recombination were identified by Southern blot analysis. Two independent recombinant ES cell clones were microinjected into FVB donor blastocysts and implanted into pseudo-pregnant females. Chimaeric mice were backcrossed to C57BL/6J mice and germline transmission of the Craf LSLD468A allele was confirmed by Southern blot analysis. The targeting vector used to obtain the Kras FSFG12V allele was generated by Taconic Artemis. In brief, the homology arms including the first exon containing the oncogenic G12V mutation were amplified by PCR using as a template a targeting vector previously developed to generate a Kras LSLG12Vgeo allele 9 .
A PGK-Neo-STOP cassette was generated by PCR amplification of the 1,377 bp STOP cassette derived from the Kras LSLG12Vgeo targeting vector with primers that incorporated NdeI restriction sites. The STOP cassette was subsequently cloned into the NdeI restriction site of pBASIC10 (Taconic Artemis) flanked by FRT sequences. The resulting targeting vector was linearized with NotI and electroporated into B6129SF1/J ES cells. Two independent recombinant ES cell clones were microinjected into C57BL/6J blastocysts and transplanted into pseudo-pregnant females. Chimaeric mice were backcrossed to C57BL/6J mice and germ line transmission of the targeted allele was confirmed by Southern blot analysis. All animal experiments were approved by the Ethical Committee of CNIO and performed in accordance with the guidelines stated in the International Guiding Principles for Biomedical Research Involving Animals, developed by the Council for International Organizations of Medical Sciences (CIOMS). All strains were genotyped by Transnetyx. Tumour induction and drug treatments. Tumours were induced in 8-to 12-weekold mice (both male and female animals were used) by single intratracheal infection with 10 6 adenoviral particles (unless stated otherwise) after anaesthesia (i.p. injection of ketamine 75 mg kg lung adenocarcinoma cell lines were generated from primary tumours. Cells were infected with lentiviruses expressing Braf, Braf(D631A) and Craf (pLVXpuro) using routine procedures and exposed to 50 MOI (multiplicity of infection) of Ad-Cre. 4-hydroxytamoxifen (4-OHT) (Sigma) was used at 600 nM. Cell lines were confirmed mycoplasma free at every freeze/thaw cycle. Primary keratinocytes were obtained from adult tail skin. The antibodies used for western blotting included those raised against: Araf (Cell Signaling Technology, 4432); Braf (Santa Cruz Biotechnology, SC-5284); Craf (BD Biosciences, 610151); p-Erk1/2 (Cell Signaling Technology, 9101); Erk1 (BD Biosciences, 554100); Erk2 (BD Biosciences, 610103); γ-H2AX (Millipore, 05-636); p-p90Rsk (Cell Signaling Technology, 9341); p90Rsk (Santa Cruz Biotechnology, SC-231); p53 (Cell Signaling Technology, 2524); p19 ARF (Abcam, ab80); cleaved caspase-3 (Cell Signaling Technology, 9661) and Gapdh (Sigma, G8795). Computed tomography. Mice were anaesthetized with 1% to 3% flow of isoflurane/oxygen, and the chest area was visualized with the GE eXplore Locus micro PET-CT scanner (GE Healthcare). The resulting raw data were reconstructed to a final image volume of 875 × 875 × 465 slices at 93 μm 3 voxel dimensions. Reconstructed slices were output in the manufacturer's raw format and corrected equal to Hounsfield units and analysed with MicroView analysis software (GE Healthcare). Digital image quantification. Digital images of immunostained slides were obtained using a whole slide scanner (Dotslide Olympus) with resolution 0.32 μm per pixel (20×/NA 0.75). For automated image quantification the tumour areas on scanned H&E sections were manually delimited within the normal lung tissue according to histological criteria and quantified by Dotslide viewer software. Statistical and data analysis. The product limit method of Kaplan and Meier was used for generating the survival curves, which were compared by using the log-rank (Mantel-Cox) test. A P value that was less than 0.05 was considered statistically significant for all datasets. All statistical analysis was performed using GraphPad Prism software. No statistical method was used to predetermine sample size in animal studies. Only mice carrying tumours >1 mm in diameter on CT were enrolled in longitudinal studies assessing tumour volume variation. For all animal experiments block randomization was used to ensure a balance in sample size across groups over time. The investigators were blinded during evaluation of tumour size variations following tamoxifen diet. Data availability. All data generated or analysed during this study are included in this published article (and its Supplementary Information files). , empty circles n = 13) mice bearing lung adenocarcinomas detectable by CT. Upon tumour detection mice were maintained on a tamoxifencontaining diet to activate expression of the Braf(D631A) kinase-dead isoform. P < 0.0058, obtained using the log-rank test (Mantel-Cox). b, Waterfall plot representation of the tumour volume increase (measured as fold change) when re-evaluated by CT after 8 weeks of continuous tamoxifen-containing diet in Kras +/FSFG12V ;Braf +/LSLD631A ;Tg.hUb-cre-ERT2 +/T (K F B, n = 29 tumours from 14 mice) and control Kras +/FSFG12V ; Tg.hUb-cre-ERT2 +/T (K F , n = 38 tumours from 15 mice) cohorts. The same dataset is represented in Fig. 4a .
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